Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Tempus AI, Inc. - SIC # 8081 -
Ticker
Exchange
SIC #
Website
Latest Ticker
TEM
Nasdaq
8081
www.tempus.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Tempus AI, Inc.
TEM Stock On Track For Best Week In 4 Months Following Personalis Deal Spotlight
- Aug 20th, 2026 11:22 am
Moderna’s Cancer Breakthrough Just Made Tempus AI’s $1.5 Billion Bet Look Brilliant
- Aug 19th, 2026 12:44 pm
TEM, BNTX, MRVI, RGEN, NVAX Stock Rallies As Moderna-Merck Cancer Vaccine Clears Late-stage Trial
- Aug 19th, 2026 11:49 am
Tempus AI's FDA Win Could Unlock Major Reimbursement Growth Ahead
- Aug 13th, 2026 7:07 am
Is Tempus AI Worth Buying as Growth Improves but Valuation Stays High?
- Aug 12th, 2026 8:55 am
The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It’s Not Tech)
- Aug 11th, 2026 12:00 pm
Tempus Q2 Earnings Call Highlights Data Growth and Pricing Upside
- Aug 11th, 2026 8:32 am
CellCarta Adds Tempus to CDx Commercialization Lab Network
- Aug 6th, 2026 7:15 am
[Latest] Global Generative AI In Clinical Trials Market Size/Share Worth USD 1.86 Billion by 2035 at a 9.63% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
- Aug 5th, 2026 10:30 am
[Latest] Global AI In Digital Pathology Market Size/Share Worth USD 5.14 Billion by 2035 at a 18.02% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
- Aug 5th, 2026 4:30 am
Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications
- Aug 4th, 2026 6:30 am
How Investors May Respond To Tempus AI (TEM) Q2 Profit Return, Outlook Hike, Personalis Deal
- Aug 1st, 2026 8:10 am
Tempus AI Q2 Earnings Call Highlights
- Jul 31st, 2026 8:03 pm
Beyond Mega IPOs: ICR Capital President & Chairman Don Duffy, Live from NYSE
- Jul 31st, 2026 11:12 am
Scroll